Pricing wars heat up over hepatitis C drugs
The race for better hepatitis C treatments is in full swing with the approval of another all-oral drug regimen. The U.S. Food and Drug Administration (FDA) approved AbbVie’s new multi-drug combination, Viekira Pak, on December 19 last year, heightening the competition in the hepatitis C arena.
Sovaldi, Gilead’s oral treatment for hepatitis C costing $1,000 per pill, was cleared in the U.S. in December 2013, followed by the FDA approval of Harvoni at a cost of $1,125 per pill in October of last year. These two new Gilead drugs were launched at prices of $84,000 and $94,500 respectively for a 12-week regimen. In a battle to grab market share, AbbVie’s rival hepatitis C drug Viekira Pak costs $83,319 for a standard 12-week regimen.
Exploring HCV in Brazil
Brazil has developed a strong commitment to universal access to healthcare and now promotes a “health for all” vision that is providing more advanced treatments to a whole new class of patient.
This has caused the healthcare challenges to shift from a lack of availability, to discussions about willingness to spend limited resources and effective allocation of treatment. All of which has led to Brazil becoming one of the world’s largest pharma markets.
World Hepatitis Day, 28th July 2014
28th July marks World Hepatitis Day, a drive to increase the awareness and understanding of viral hepatitis and marks an opportunity to think about how we can influence change for better.
28th July marks World Hepatitis Day, a drive to increase the awareness and understanding of viral hepatitis and marks an opportunity to think about how we can influence change for better. The ‘Think Again’ campaign encourages people to challenge our perceptions of hepatitis, and aims to get people thinking again about what they think they know (or don’t know) about the disease. As part of this we have been encouraged to send in pictures which have challenged us to think again about the world we live in, and what we can do to help spread the word about hepatitis.
Achieving early insights into a new drug launch
After releasing a new drug for HCV, our client wanted to be able to regularly track uptake of their product.
They wanted to see how the market would react to the new drug and gain quantitative insight into breadth of prescribing, patient profiles and segments, and identify changes in prescribing behaviour over time as soon as possible.